Health

Companies engaged in biotechnology, pharmaceuticals, research services, home healthcare, hospital operations, long‑term care, and the manufacture and supply of medical equipment and supplies. The sector also includes pharmaceutical retailers and providers of health‑information services. UK‑listed companies in this sector include AstraZeneca plc, GlaxoSmithKline plc, Smith & Nephew plc, Hikma Pharmaceuticals plc, ConvaTec Group plc, Spire Healthcare plc and EMIS Group plc.

GSK Plc Shingrix new prefilled syringe presentation accepted for review by EMA

GSK's innovative prefilled Shingrix syringe gains EMA review, aiming to simplify shingles prevention for healthcare professionals across Europe...

AstraZeneca Plc Datroway approved in the US for metastatic breast cancer

AstraZeneca and Daiichi Sankyo's Datroway gains FDA approval, offering a new treatment option for specific metastatic breast cancer cases...

GSK’s Jemperli gains EU approval for advanced endometrial cancer treatment

GSK's Jemperli plus chemotherapy gains EU approval for broader use in first-line treatment of advanced or recurrent endometrial cancer, improving survival rates...

FDA accepts review of GSK Plc’s prefilled Shingrix syringe for vaccine approval

GSK's Shingrix aims for FDA-approved prefilled syringe to simplify shingles vaccination, enhancing convenience for healthcare providers...

GSK Plc’s ADC receives US FDA Breakthrough Therapy Designation

GSK's ADC GSK5764227 gains FDA Breakthrough Therapy status for treating relapsed or refractory osteosarcoma, addressing critical unmet medical needs...

GSK Plc’s Nucala approved in China as a treatment for CRSwNP

GSK's Nucala has been approved in China as an add-on treatment for CRSwNP, marking the first anti-IL-5 therapy for adults with this chronic condition...

AstraZeneca’s Tagrisso approved in the EU for patients with unresectable NSCLC

AstraZeneca's Tagrisso gains EU approval for treating advanced NSCLC, showing significant efficacy in reducing disease progression in key trials...

GSK Plc FIRST trial meetss primary endpoint in ovarian cancer

GSK reports success in phase III trial of Zejula and Jemperli for advanced ovarian cancer, achieving significant progression-free survival improvement...

GSK Plc receives US FDA Breakthrough Therapy Designation

GSK's Jemperli receives FDA Breakthrough Therapy Designation for treating locally advanced dMMR/MSI-H rectal cancer, expediting crucial development...

GSK Plc Nucala COPD submission accepted by FDA

GSK announces FDA review of Nucala for COPD treatment following successful MATINEE study data, aiming to be the first approved monthly biologic...

AstraZeneca Plc Imfinzi approved in the US for limited-stage SCLC

AstraZeneca's Imfinzi receives FDA approval for limited-stage small cell lung cancer, marking a significant breakthrough in extending patient survival...

GSK plc RSV vaccine Arexvy approved in Japan

GSK's Arexvy vaccine receives approval in Japan to protect adults aged 50-59 at increased risk from severe RSV infection, expanding its coverage...

AstraZeneca Plc expands US R&D and manufacturing footprint with $3.5b investment

AstraZeneca Plc commits $3.5 billion to boost US research and manufacturing by 2026, creating jobs and expanding its innovation footprint...

AstraZeneca Plc Tezspire meets primary endpoints in WAYPOINT trial

AstraZeneca and Amgen's Tezspire shows promise in reducing nasal polyp size and congestion, offering hope for chronic rhinosinusitis patients...

Haleon Plc reports strong Q3 organic revenue growth, guidance reaffirmed

Haleon plc releases its Q3 2024 trading update, now available for review. Join the presentation on October 31 for in-depth analysis and insights...

GSK Plc confirms 2024 guidance; Q3 dividend of 15p declared

GSK Plc reports Q3 2024 results with strong growth in Specialty Medicines offsetting lower Vaccine sales. Core earnings rose by 5%, despite Zantac charges...

AstraZeneca’s Wainzua recommended for approval in the UK

AstraZeneca's Wainzua gains CHMP backing for EU approval in treating ATTRv-PN, marking a potential breakthrough with self-administered therapy...

FDA accepted New Drug Application for GSK’s Gepotidacin

GSK's new antibiotic gepotidacin earns FDA's Priority Review, marking potential first new uUTI oral treatment in 20 years, with decision due March 2025...
Search

Funds

Health

GSK Plc Shingrix new prefilled syringe presentation accepted for review by EMA

GSK's innovative prefilled Shingrix syringe gains EMA review, aiming to simplify shingles prevention for healthcare professionals across Europe...

AstraZeneca Plc Datroway approved in the US for metastatic breast cancer

AstraZeneca and Daiichi Sankyo's Datroway gains FDA approval, offering a new treatment option for specific metastatic breast cancer cases...

GSK’s Jemperli gains EU approval for advanced endometrial cancer treatment

GSK's Jemperli plus chemotherapy gains EU approval for broader use in first-line treatment of advanced or recurrent endometrial cancer, improving survival rates...

FDA accepts review of GSK Plc’s prefilled Shingrix syringe for vaccine approval

GSK's Shingrix aims for FDA-approved prefilled syringe to simplify shingles vaccination, enhancing convenience for healthcare providers...

GSK Plc’s ADC receives US FDA Breakthrough Therapy Designation

GSK's ADC GSK5764227 gains FDA Breakthrough Therapy status for treating relapsed or refractory osteosarcoma, addressing critical unmet medical needs...

GSK Plc’s Nucala approved in China as a treatment for CRSwNP

GSK's Nucala has been approved in China as an add-on treatment for CRSwNP, marking the first anti-IL-5 therapy for adults with this chronic condition...

AstraZeneca’s Tagrisso approved in the EU for patients with unresectable NSCLC

AstraZeneca's Tagrisso gains EU approval for treating advanced NSCLC, showing significant efficacy in reducing disease progression in key trials...

GSK Plc FIRST trial meetss primary endpoint in ovarian cancer

GSK reports success in phase III trial of Zejula and Jemperli for advanced ovarian cancer, achieving significant progression-free survival improvement...

GSK Plc receives US FDA Breakthrough Therapy Designation

GSK's Jemperli receives FDA Breakthrough Therapy Designation for treating locally advanced dMMR/MSI-H rectal cancer, expediting crucial development...

GSK Plc Nucala COPD submission accepted by FDA

GSK announces FDA review of Nucala for COPD treatment following successful MATINEE study data, aiming to be the first approved monthly biologic...

AstraZeneca Plc Imfinzi approved in the US for limited-stage SCLC

AstraZeneca's Imfinzi receives FDA approval for limited-stage small cell lung cancer, marking a significant breakthrough in extending patient survival...

GSK plc RSV vaccine Arexvy approved in Japan

GSK's Arexvy vaccine receives approval in Japan to protect adults aged 50-59 at increased risk from severe RSV infection, expanding its coverage...

AstraZeneca Plc expands US R&D and manufacturing footprint with $3.5b investment

AstraZeneca Plc commits $3.5 billion to boost US research and manufacturing by 2026, creating jobs and expanding its innovation footprint...

AstraZeneca Plc Tezspire meets primary endpoints in WAYPOINT trial

AstraZeneca and Amgen's Tezspire shows promise in reducing nasal polyp size and congestion, offering hope for chronic rhinosinusitis patients...

Haleon Plc reports strong Q3 organic revenue growth, guidance reaffirmed

Haleon plc releases its Q3 2024 trading update, now available for review. Join the presentation on October 31 for in-depth analysis and insights...

GSK Plc confirms 2024 guidance; Q3 dividend of 15p declared

GSK Plc reports Q3 2024 results with strong growth in Specialty Medicines offsetting lower Vaccine sales. Core earnings rose by 5%, despite Zantac charges...

AstraZeneca’s Wainzua recommended for approval in the UK

AstraZeneca's Wainzua gains CHMP backing for EU approval in treating ATTRv-PN, marking a potential breakthrough with self-administered therapy...

FDA accepted New Drug Application for GSK’s Gepotidacin

GSK's new antibiotic gepotidacin earns FDA's Priority Review, marking potential first new uUTI oral treatment in 20 years, with decision due March 2025...
Search

Funds

Health

FTSE 100

Funds